Research location
Jaú
São Paulo, Brazil
Advertisement
Research activity in Jaú
São Paulo, BrazilCureCurrent currently publishes aggregate city-level research activity for this location: 58 trials and 61 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Jaú
58 linked trials · page 1 of 2A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)NCT06452277 · 2024-08-28 · 1 site observation
RECRUITING
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)NCT06330064 · 2024-04-10 · 1 site observation
RECRUITING
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor ResectionNCT07128199 · 2025-12-22 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung CancerNCT06012435 · 2024-02-21 · 1 site observation
ACTIVE_NOT_RECRUITING
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)NCT06117774 · 2024-02-20 · 1 site observation
ACTIVE_NOT_RECRUITING
REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)NCT05973773 · 2023-12-18 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)NCT06065748 · 2023-12-11 · 1 site observation
ACTIVE_NOT_RECRUITING
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast CancerNCT06016738 · 2023-11-16 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related ComorbiditiesNCT05869903 · 2023-06-05 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Botensilimab and Balstilimab for the Treatment of Colorectal CancerNCT05608044 · 2022-11-30 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast CancerNCT05132582 · 2022-03-07 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)NCT04961996 · 2021-08-27 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are OverweightNCT04657003 · 2021-03-29 · 1 site observation
COMPLETED
A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without MetforminNCT04537923 · 2020-10-19 · 1 site observation
COMPLETED
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 DiabetesNCT04255433 · 2020-05-29 · 1 site observation
COMPLETED
Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)NCT04246177 · 2020-05-22 · 1 site observation
TERMINATED
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)NCT04191096 · 2020-02-12 · 1 site observation
TERMINATED
Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBCNCT03562637 · 2018-12-05 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast CancerNCT03498716 · 2018-08-02 · 1 site observation
TERMINATED
Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])NCT03517449 · 2018-06-11 · 1 site observation
COMPLETED
Study to Evaluate the Safety and Efficacy of Switching From Zoladex® Monthly or Quarterly, to Eligard® Semiannual.NCT05304169 · 2017-11-14 · 1 site observation
COMPLETED
A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate CancerNCT03148795 · 2017-07-04 · 1 site observation
COMPLETED
Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)NCT03142334 · 2017-06-09 · 1 site observation
COMPLETED
Evaluation of Orlistat as Adjuvant Treatment of Obesity in AdultsNCT01755676 · 2016-09-01 · 1 site observation
COMPLETED
Avelumab in First-line NSCLC (JAVELIN Lung 100)NCT02576574 · 2015-10-29 · 1 site observation
COMPLETED
A Study for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer PatientsNCT03127631 · 2015-10-21 · 1 site observation
ACTIVE_NOT_RECRUITING
Metastatic Breast Cancer in Brazil: Characterization of Patients and TreatmentsNCT02662868 · 2015-06-01 · 1 site observation
COMPLETED
Retrospective Data Collection: Post Study Treatment Anticancer Therapy From IMELDA MO22223NCT02383576 · 2015-04-30 · 1 site observation
COMPLETED
Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate CancerNCT02200614 · 2014-09-12 · 1 site observation
COMPLETED
Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate CancerNCT02003924 · 2013-10-31 · 3 site observations
COMPLETED
A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)NCT01945775 · 2013-10-14 · 1 site observation
COMPLETED
Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Women With HER2-positive Early Breast CancerNCT01901146 · 2013-04-29 · 1 site observation
COMPLETED
A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast CancerNCT01572038 · 2012-06-01 · 1 site observation
COMPLETED
A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast CancerNCT01566721 · 2012-05-17 · 1 site observation
COMPLETED
Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without Pictilisib in Previously Untreated Advanced or Recurrent Non-small Cell Lung CancerNCT01493843 · 2012-01-20 · 1 site observation
COMPLETED
A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)NCT01456325 · 2012-01-01 · 1 site observation
COMPLETED
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) GeneNCT00932451 · 2010-01-01 · 1 site observation
COMPLETED
Safety Study in Subjects With Metastatic Breast Cancer Who Progressed After Taxanes Treatment.NCT01050322 · 2009-11-01 · 1 site observation
COMPLETED
A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast CancerNCT00950300 · 2009-10-16 · 1 site observation
COMPLETED
An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) GeneNCT00932893 · 2009-09-01 · 1 site observation
COMPLETED
A Study of Avastin (Bevacizumab) + Xeloda (Capecitabine)as Maintenance Therapy in Patients With HER2-Negative Metastatic Breast CancerNCT00929240 · 2009-07-01 · 1 site observation
COMPLETED
Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to ImatinibNCT00802841 · 2009-05-01 · 1 site observation
COMPLETED
A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).NCT00661102 · 2008-12-01 · 1 site observation
COMPLETED
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate CancerNCT00744497 · 2008-10-01 · 1 site observation
COMPLETED
BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus BevacizumabNCT00625898 · 2008-04-01 · 1 site observation
TERMINATED
Alimta® Versus Its Combination With Carboplatin in Advanced Non-small-cell Lung Cancer in Patients Performance Status 2NCT01836575 · 2008-04-01 · 1 site observation
COMPLETED
A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast CancerNCT00567190 · 2008-02-12 · 1 site observation
COMPLETED
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063DNCT00490139 · 2007-05-16 · 1 site observation
COMPLETED
A Phase III Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients With Stage IIIb With Effusion and Stage IV Non-Small Cell Lung Cancer (NSCLC)NCT00449033 · 2007-02-01 · 1 site observation
COMPLETED
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)NCT00409188 · 2007-01-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.